A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 4, 2015, Pages 793-801

  Fujita, Ken Ichi ^a,d   Yoshino, Etsuko ^a   Kawara, Kaori ^a   Maeda, Kazuya ^b   Kusuhara, Hiroyuki ^b   Sugiyama, Yuichi ^b,c   Yokoyama, Taro ^a   Kaneta, Toshikado ^a,d   Ishida, Hiroo ^a,d   Sasaki, Yasutsuna ^a,d  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c RIKEN   (Japan)

^d SHOWA UNIVERSITY   (Japan)

Author keywords

Docetaxel; Microdose study; Pharmacokinetics; 1 acid glycoprotein

Indexed keywords

DOCETAXEL; OROSOMUCOID; PACLITAXEL; ANTINEOPLASTIC AGENT; NEW DRUG; TAXOID; TUBULIN MODULATOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MICRODOSE; FEMALE; HUMAN; JAPANESE (PEOPLE); MALE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; AGED; BIOLOGICAL MODEL; BLOOD; DOSE RESPONSE; DRUG SCREENING; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASMS; PROCEDURES;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUGS, INVESTIGATIONAL; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; OROSOMUCOID; TAXOIDS; TUBULIN MODULATORS;

EID: 84942198810     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2844-2     Document Type: Article

References (19)

1. Food and Drug Administration (2006) Guidance for industry, investigators, and reviewers: exploratory IND studies, FDA. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078933.pdf#search='Guidance+for+industry%2C+investigators%2C+and+reviewers%3A+exploratory+IND+studies.+US+department+of+health+and+human+services. Accessed 1 April 2015
2. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC (2006) Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 80:203-215
3. Ieiri I, Nishimura C, Maeda K, Sasaki T, Kimura M, Chiyoda T, Hirota T, Irie S, Shimizu H, Noguchi T, Yoshida K, Sugiyama Y (2011) Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genomics 21:495-505
4. Kusuhara H, Furuie H, Inano A, Sunagawa A, Yamada S, Wu C, Fukizawa S, Morimoto N, Ieiri I, Morishita M, Sumita K, Mayahara H, Fujita T, Maeda K, Sugiyama Y (2012) Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br J Pharmacol 166:1793-1803
5. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, Sugiyama Y (2011) Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 89:837-844
6. Maeda K, Takano J, Ikeda Y, Fujita T, Oyama Y, Nozawa K, Kumagai Y, Sugiyama Y (2011) Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. Clin Pharmacol Ther 90:263-270
7. Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99-114
8. McLeod HL, Kearns CM, Kuhn JG, Bruno R (1998) Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemother Pharmacol 42:155-159
9. Minami H, Kawada K, Sasaki Y, Tahara M, Igarashi T, Itoh K, Fujii H, Saeki T, Ozawa K, Sato H (2009) Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci 100:144-149
10. Urien S, Barre J, Morin C, Paccaly A, Montay G, Tillement JP (1996) Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs 14:147-151
11. Food and Drug Administration (2014) Highlights of prescribing information for docetaxel. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/020449s073lbl.pdf. Accessed 1 April 2015
12. Nieuweboer AJ, Hu S, Gui C, Hagenbuch B, Ghobadi Moghaddam-Helmantel IM, Gibson AA, de Bruijn P, Mathijssen RH, Sparreboom A (2014) Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res 74:3137-3145
13. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y (2008) Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci 99:967-972
14. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095
15. van der Veldt AA, Lubberink M, Mathijssen RH, Loos WJ, Herder GJ, Greuter HN, Comans EF, Rutten HB, Eriksson J, Windhorst AD, Hendrikse NH, Postmus PE, Smit EF, Lammertsma AA (2013) Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [11C]docetaxel and positron emission tomography. Clin Cancer Res 19:4163-4173
16. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123
17. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23-34
18. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, Investigators K (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532
19. Sugiyama Y, Yamashita S (2011) Impact of microdosing clinical study - why necessary and how useful? Adv Drug Deliv Rev 63:494-502